1月15日,美国生物技术公司Ocugen公布其AAV5基因疗法OCU410在ArMaDa II期试验的初步数据,显示该药显著减缓干性AMD继发GA病变进展。公司计划本季度公布完整数据,并于2026年启动III期试验,目标2028年提交上市申请。1月15日,Ocugen公布了ArMaDa II期临床试验的初步数据。该试验旨在研究其基因疗法OCU410治疗干性年龄相关性黄斑变性(AMD)继发地图状萎缩...
Source Link1月15日,美国生物技术公司Ocugen公布其AAV5基因疗法OCU410在ArMaDa II期试验的初步数据,显示该药显著减缓干性AMD继发GA病变进展。公司计划本季度公布完整数据,并于2026年启动III期试验,目标2028年提交上市申请。1月15日,Ocugen公布了ArMaDa II期临床试验的初步数据。该试验旨在研究其基因疗法OCU410治疗干性年龄相关性黄斑变性(AMD)继发地图状萎缩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.